/GLSI
GLSI Stock - Greenwich LifeSciences, Inc.
Healthcare|BiotechnologyNASDAQ
$13.01+5.00%
+$0.62 (+5.00%) • Dec 19
57
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.86
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.3
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $14.31
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for GLSI
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$12.88 – $13.14
TARGET (TP)$14.96
STOP LOSS$11.97
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta2.92
52W High$14.47
52W Low$7.78
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | $-3,612 | $-3,612 | $-3,612 | $-3,612 | $-3,609 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-16,011,817 | $-9,327,866 | $-8,040,254 | $-4,597,943 | $-1,863,794 |
| Net Income | $-15,788,809 | $-8,891,803 | $-7,825,237 | $-4,570,576 | $-1,862,130 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-1.21 | $-0.69 | $-0.61 | $-0.35 | $-0.15 |
Company Overview
Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
1
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
1 Bullish0 Neutral/Bearish
Price Targets
$45
Average Target
↑ 245.9% Upside
Now
$45
Low
$45
Average
$45
High
Based on 1 analyst
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| August 20th 2025 | Noble Capital Markets | Initiation | Outperform | $45 |
Earnings History & Surprises
GLSIBeat Rate
50%
Last 18 quarters
Avg Surprise
-8.5%
EPS vs Estimate
Beats / Misses
9/7
2 met exactly
Latest EPS
$-0.30
Q4 2025
EPS Surprise History
Q2 24
-5.0%
$-0.21vs$-0.20
Q2 24
+5.0%
$-0.19vs$-0.20
Q3 24
0.0%
$-0.20vs$-0.20
Q4 24
+4.8%
$-0.20vs$-0.21
Q2 25
-190.5%
$-0.61vs$-0.21
Q2 25
-4.2%
$-0.25vs$-0.24
Q3 25
-25.0%
$-0.30vs$-0.24
Q4 25
0.0%
$-0.30vs$-0.30
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Apr 21, 2026 | $-0.34 | — | — | — |
Q4 2025 | Nov 14, 2025 | $-0.30 | $-0.30 | 0.0% | = MET |
Q3 2025 | Aug 14, 2025 | $-0.24 | $-0.30 | -25.0% | ✗ MISS |
Q2 2025 | May 20, 2025 | $-0.24 | $-0.25 | -4.2% | ✗ MISS |
Q2 2025 | Apr 15, 2025 | $-0.21 | $-0.61 | -190.5% | ✗ MISS |
Q4 2024 | Nov 14, 2024 | $-0.21 | $-0.20 | +4.8% | ✓ BEAT |
Q3 2024 | Aug 14, 2024 | $-0.20 | $-0.20 | 0.0% | = MET |
Q2 2024 | May 20, 2024 | $-0.20 | $-0.19 | +5.0% | ✓ BEAT |
Q2 2024 | Apr 15, 2024 | $-0.20 | $-0.21 | -5.0% | ✗ MISS |
Q4 2023 | Oct 19, 2023 | $-0.22 | $-0.19 | +13.6% | ✓ BEAT |
Q3 2023 | Aug 21, 2023 | $-0.23 | $-0.13 | +43.5% | ✓ BEAT |
Q2 2023 | May 22, 2023 | $-0.23 | $-0.17 | +26.1% | ✓ BEAT |
Q1 2023 | Mar 31, 2023 | $-0.18 | $-0.22 | -22.2% | ✗ MISS |
Q4 2022 | Nov 14, 2022 | $-0.19 | $-0.18 | +5.3% | ✓ BEAT |
Q3 2022 | Aug 15, 2022 | $-0.19 | $-0.06 | +68.4% | ✓ BEAT |
Q2 2022 | May 20, 2022 | $-0.19 | $-0.15 | +21.1% | ✓ BEAT |
Q1 2022 | Mar 21, 2022 | $-0.07 | $-0.18 | -157.1% | ✗ MISS |
Q4 2021 | Nov 15, 2021 | $-0.06 | $-0.07 | -16.7% | ✗ MISS |
Q3 2021 | Aug 13, 2021 | — | $-0.06 | — | — |
Q2 2021 | May 20, 2021 | $-0.26 | $-0.05 | +80.8% | ✓ BEAT |
Latest News
GLSI stock has given up its prior gain. Greenwich LifeSciences shares were trading higher after the company reported early FLAMINGO-01 trial results showing an 80% reduction in cancer recurrences.
➖ NeutralBenzinga•Dec 15, 2025, 08:48 PM
Greenwich LifeSciences shares are trading higher after the company reported early FLAMINGO-01 trial results showing an 80% reduction in cancer recurrences.
📈 PositiveBenzinga•Dec 15, 2025, 03:54 PM
Greenwich LifeSciences Reports Early FLAMINGO-01 Results Showing 80% Reduction In Cancer Recurrences
📈 PositiveBenzinga•Dec 15, 2025, 11:09 AM
Greenwich Lifesciences Completed Enrollment In Open-Label HLA-A*02 Arm of FLAMINGO-01 Phase 3 Trial Of GLSI-100, An Immunotherapy To Prevent Breast Cancer Recurrences
📈 PositiveBenzinga•Dec 8, 2025, 11:04 AM
Greenwich Lifesciences Announces Phase 3 FLAMINGO-01 Trial Of GLSI-100, An Immunotherapy To Prevent Breast Cancer Recurrences, Has Achieved A Major Milestone By Screening Over 1,000 Patients
📈 PositiveBenzinga•Dec 3, 2025, 11:05 AM
Greenwich LifeSciences Expands Phase III Flamingo-01 Breast Cancer Trial To Austria Following Regulatory Approval
📈 PositiveBenzinga•Oct 9, 2025, 10:10 AM
Greenwich LifeSciences Strengthens European Presence As Flamingo-01 Clinical Trial Adds Belgium To Nine Approved Countries
📈 PositiveBenzinga•Oct 2, 2025, 10:08 AM
Greenwich LifeSciences Takes Fight Against Breast Cancer Recurrence Global with Trial Expansion into Portugal
📈 PositiveBenzinga•Sep 30, 2025, 10:12 AM
Greenwich LifeSciences Expands Phase III Flamingo-01 Breast Cancer Immunotherapy Trial To Ireland
📈 PositiveBenzinga•Sep 18, 2025, 10:11 AM
Greenwich LifeSciences shares are trading higher after the FDA granted Fast Track designation for GLSI-100 in the HLA-A*02 patient population.
📈 PositiveBenzinga•Sep 10, 2025, 01:20 PM
Greenwich LifeSciences soars on FDA Fast Track status for lead asset
📈 PositiveSeeking Alpha•Sep 10, 2025, 10:55 AM
The FDA Has Granted Fast Track Designation To Greenwich Lifesciences' GLSI-100 In HLA-A*02 Patient Population
📈 PositiveBenzinga•Sep 10, 2025, 10:03 AM
Greenwich LifeSciences Cuts Costs by Bringing Breast Cancer Trial Management In-House
➖ NeutralBenzinga•Aug 19, 2025, 10:04 AM
Frequently Asked Questions about GLSI
What is GLSI's current stock price?
Greenwich LifeSciences, Inc. (GLSI) is currently trading at $13.01 per share. The stock has moved +5.00% today.
What is the analyst price target for GLSI?
No analyst price targets are currently available for this stock.
What sector is Greenwich LifeSciences, Inc. in?
Greenwich LifeSciences, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is GLSI's market cap?
Greenwich LifeSciences, Inc. has a market capitalization of $0.18 billion, making it a small-cap company.
Does GLSI pay dividends?
No, Greenwich LifeSciences, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAGEN
Agenus Inc.
$3.44
Mkt Cap: $0.1B
ATOS
Atossa Therapeutics, Inc.
$0.73
Mkt Cap: $0.1B
CGTX
Cognition Therapeutics, Inc.
$1.54
Mkt Cap: $0.1B
HURA
TuHURA Biosciences, Inc.
$0.82
Mkt Cap: $0.0B
IMMX
Immix Biopharma, Inc.
$5.72
Mkt Cap: $0.2B
IRD
Opus Genetics, Inc.
$2.00
Mkt Cap: $0.1B
ONCY
Oncolytics Biotech Inc.
$1.01
Mkt Cap: $0.1B
SEER
Seer, Inc.
$1.79
Mkt Cap: $0.1B
SRZN
Surrozen, Inc.
$21.76
Mkt Cap: $0.2B
TVGN
Tevogen Bio Holdings Inc.
$0.38
Mkt Cap: $0.1B
Explore stocks similar to GLSI for comparison